FPRX Five Prime Therapeutics Inc.

+0.54  (+6%)
Previous Close 8.83
Open 8.86
Price To Book 1.44
Market Cap 337906356
Shares 36,062,578
Volume 282,013
Short Ratio
Av. Daily Volume 312,303

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 futility analysis due 1H 2020.
FPA144 + chemo (FIGHT)
Gastric and gastro-esophageal junction cancer
Phase 1b ongoing.
Cabiralizumab (FPA008) and Opdivo (nivolumab)
Solid tumors
Phase 2 complete. Phase 3 development will not be pursued.
Cabiralizumab (FPA008)
Pigmented Villonodular Synovitis (PVNS)
Phase 1b NSCLC halted, mesothelioma to continue. Data at ESMO showed ORR 48%.
Mesothelioma cancer
Phase 1b commencement of dosing announced February 21, 2019. Initial data due at ASCO June 1 2019, 8am.
Solid tumors
Phase 2 trial initiated January 2018.
Cabiralizumab (FPA008) and Opdivo (nivolumab)
Pancreatic cancer
Phase 1 dosing announced November 14, 2018. Data due 2019.
Solid tumors